Replies to post #254877 on Biotech Values

[DewDiligence]

Isaac's most salient point, IMO, is that the Chinese datasets for the most part have not yet been subjected to reviews by developed-market regulators, so we don't yet know how well the datasets will stand up to scrutiny.